Question Bank › Order-of-magnitude gap

Order-of-magnitude gap

Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business

Calls Tested
489
Answered YES
13
Hit Rate
2.7%
rare by design

Biogen Inc. (BIIB) — this company's answers

NO on the Q2 2017 call 2017-07-25 B
The model's full reasoning — Q2 2017 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司规模与已服务需求之间的“规模不匹配”——即公司当前供应、服务或参与的某事物,其规模、支出、数量或人口相对于公司自身当前业务而言巨大,以至于即使再获得一小部分份额,也能使公司规模扩大数倍。 分析要点: 1. 公司是否已实际参与其中,并有真实业务可指。 2. 管理层是否明确对比了规模差异,并将其视为重点。 在记录中,管理层多次提到: - MS业务:全球患者340,000人,但市场仍有大量未治疗患者(如美国仅一半患者接受治疗),但这是市场潜力,并非已参与的巨大流量。 - SPINRAZA:提到美国有145个给药点,233个提交表格,但未明确对比公司规模与潜在患者总数。 - 生物类似药:提到BENEPALI在20个国家可用,市场份额等,但未强调规模不匹配。 - 战略更新:提到“神经科学是下一个肿瘤学”,但这是行业前景,非具体已参与的巨大流量。 关键点:管理层是否明确说“我们只捕获了很小一部分”?在SPINRAZA部分,提到“我们相信SPINRAZA将成为我们最大的商业资产之一”,但未量化对比。在MS部分,提到“我们维持全球市场份额”,但未强调公司规模与市场规模的差距。 在回答中,管理层提到“我们估计美国有约12,000名SMA患者”,但未明确说公司已服务其中多少,或对比公司规模。此外,提到“我们相信SPINRAZA将成为我们最大的商业资产之一”,但未说“我们只占市场的X%”。 在战略部分,提到“我们旨在成为神经科学领导者”,但未具体描述已参与的巨大流量。 因此,管理层没有明确描述一个“公司已参与其中,且其规模远大于公司”的具体情况。他们更多是谈论市场机会和增长潜力,而非当前已参与的巨大流量。 结论:答案应为NO。

← Back to the full BIIB analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe a MISMATCH OF SCALE between the company and the demand it is already serving — that is, does management convey that the company is currently supplying, serving, or participating in something whose size, spending, volume, or population is ENORMOUS RELATIVE TO THE COMPANY'S OWN CURRENT BUSINESS, such that even a modest further share of it would make the company several times bigger than it is today? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation with BOTH of the following present: (1) THE COMPANY IS ALREADY INSIDE IT, WITH REAL BUSINESS TO POINT TO. Management describes actual, present-tense participation — orders being filled, customers being served, product shipping, work being performed, activity running now — in something identifiable and much larger than the company: a large counterparty's or industry's ongoing spending, build-out, program, or platform; a population, installed base, fleet, or footprint the company is already qualified and selling into; a category of use, market, or channel where the company's offering is already being bought. Real current activity is required — not a pipeline, not a bid outstanding, not an approval pending, not a market the company hopes to enter. (2) MANAGEMENT ITSELF DRAWS THE SIZE CONTRAST, AND TREATS IT AS THE POINT. Management makes the disproportion explicit or unmistakable in substance — for example by noting how small a fraction of the available activity, spend, sites, accounts, or units it has captured so far; by comparing a single customer, contract, program, or location's potential against the whole company's current size; by describing how much larger the thing it serves is than what the company currently earns from it; or by explaining that its own results to date reflect only the earliest sliver of what it is already positioned inside. Management should treat this gap between its present size and the scale of what it already touches as a central fact about the company, not as a passing remark, and should ground it in the concrete activity described rather than in an abstract market-size figure. The essence is ONE phenomenon: a small business standing inside a very large flow of activity that is already reaching it, where the binding question is how much of that flow it captures rather than whether the flow exists. The industry, the nature of the large flow, and the form of the company's participation may vary widely. Answer NO if the company is large relative to what it describes, or is already a leading participant with no meaningful multiple ahead of it. NO if the large opportunity is only prospective — a market not yet entered, an approval or decision still pending, a product still being developed, a customer still being pursued — rather than something the company is already inside and already earning from. NO if the only "big opportunity" language is a generic total-addressable-market number, an industry growth statistic, or promotional talk about a huge market, with no reference to how little of it this company has taken. NO if management merely reports strong demand, a good quarter, a large backlog, or a healthy pipeline without conveying the disproportion between the company's size and what it is already serving. NO if the disproportion is described only as a dependency risk or concentration concern management is trying to reduce. NO if the gap exists only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
GDRX GoodRx Holdings, Inc. Q2 2022 2022-08-08 F
FLYW Flywire Corporation Q1 2022 2022-05-14 B+
IRTC iRhythm Technologies, Inc. Q1 2022 2022-05-07 C+
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
RELY Remitly Global, Inc. Q4 2021 2022-03-02 B
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+
HSTM HealthStream, Inc. Q3 2017 2017-10-24 C

How the model reasoned

HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.

More from the question bank

Fresh change already executed, benefit mostlUpside surprise with durable, still-buildingStrong facts, held-back storyRunning ahead of their own plan — and manageThe company itself is the constraintReady-to-run scale already paid for and now All questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.